drugset / Trial / NCT00235495

Summary

The goal of the trial is to determine whether human albumin, administered within 5 hours of symptom onset, improves the 3-month outcome of subjects with acute ischemic stroke.

Timeline

Start
2006-06
Primary completion
2013-02
Completion
2013-02

Drugs

EvaluationDrugModalityDoseRoute
Comparator Albumin Protein / enzyme biologic 2 g/kg Intravenous

Indications